Fennec Pharmaceuticals (FENC) Aperçu de l'action
Fennec Pharmaceuticals Inc. est une société biopharmaceutique à vocation commerciale aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 6/6 |
| Croissance future | 5/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
FENC Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fennec Pharmaceuticals Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$9.97 |
| Plus haut sur 52 semaines | US$10.27 |
| Plus bas sur 52 semaines | US$5.65 |
| Bêta | 0.91 |
| Variation sur 1 mois | 52.45% |
| Variation sur 3 mois | 14.07% |
| Variation sur 1 an | 25.09% |
| Variation sur 3 ans | 35.65% |
| Variation sur 5 ans | 44.28% |
| Évolution depuis l'introduction en bourse | -91.21% |
Nouvelles et mises à jour récentes
Article d’analyse • May 17
We're Not Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Mise à jour du récit • May 14
FENC: Expanding Cisplatin Ototoxicity Protection Use Will Support Future Bullish Earnings Multiple
Analysts have maintained their $18.00 price target on Fennec Pharmaceuticals, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that leave their overall valuation view unchanged. What's in the News Four abstracts on PEDMARK are set to be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, focusing on cisplatin related hearing loss and real world outcomes in patients receiving platinum based chemotherapy (Key Developments).Recent updates
Article d’analyse • May 17
We're Not Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Mise à jour du récit • May 14
FENC: Expanding Cisplatin Ototoxicity Protection Use Will Support Future Bullish Earnings Multiple
Analysts have maintained their $18.00 price target on Fennec Pharmaceuticals, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that leave their overall valuation view unchanged. What's in the News Four abstracts on PEDMARK are set to be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, focusing on cisplatin related hearing loss and real world outcomes in patients receiving platinum based chemotherapy (Key Developments).Mise à jour du récit • Apr 25
FENC: Expanding Cisplatin Ototoxicity Use Should Support Future Bullish Earnings Multiple
Analysts have adjusted their price target on Fennec Pharmaceuticals to $18.00, with the change supported by updated assumptions around revenue growth, profit margins, and a future P/E of about 12.8, in line with a recently bullish initiation from Street research. Analyst Commentary Bullish analysts are framing the updated US$18.00 price target as consistent with expectations for Fennec Pharmaceuticals to execute against current revenue and margin assumptions while trading on a P/E of about 12.8. These views generally point to a setup where, if the company delivers on its plan, the current valuation case remains intact and could support the new target level.Mise à jour du récit • Apr 10
FENC: Cisplatin Ototoxicity Niche Will Support Future Bullish Earnings Multiple
Analysts have raised their price target on Fennec Pharmaceuticals to $18.00, supported by updated assumptions on revenue growth, profit margin and future P/E, and underpinned by a recent bullish initiation from B. Riley that reflects growing confidence in the company’s outlook.Mise à jour du récit • Mar 27
FENC: Cisplatin Ototoxicity Niche Will Underpin Future Supportive Care Upside
Analysts have reaffirmed an $18 price target for Fennec Pharmaceuticals, highlighting supportive research that emphasizes Pedmark's role as a unique, approved option in oncology supportive care. They are also reassessing assumptions related to future revenue growth, profit margins and P/E expectations.
Mise à jour du récit • Mar 11
FENC: Single Oncology Supportive Care Asset Will Drive Future Upside Potential
Narrative Update: Fennec Pharmaceuticals Analysts have lifted their price target on Fennec Pharmaceuticals from $14.00 to about $15.33, citing a richer revenue outlook, higher anticipated profit margins, and a willingness to apply a lower future P/E multiple. They highlight Pedmark's position as a unique, FDA approved option in oncology supportive care, with U.S. peak sales potential referenced above $300m.Mise à jour du récit • Feb 25
FENC: Cisplatin Ototoxicity Niche Will Support Future Oncology Care Upside
Analysts are reiterating an $18 price target for Fennec Pharmaceuticals. They point to updated assumptions that include slightly lower discount rates, higher projected revenue growth and profit margins, and a modestly lower future P/E, supported by recent bullish initiations that highlight Pedmark's role as a unique oncology supportive care opportunity.Mise à jour du récit • Feb 10
FENC: Cisplatin Ototoxicity Niche Will Drive Future Supportive Care Upside
Analysts have reiterated a US$18 price target on Fennec Pharmaceuticals, supported by their view that Pedmark offers a unique, only-approved option in oncology supportive care, with what they describe as realistic peak U.S. sales potential above US$300m. Analyst Commentary Recent coverage has centered on Pedmark as a key driver for Fennec's equity story, with bullish analysts highlighting its role as the only approved agent for reducing the risk of cisplatin induced ototoxicity in oncology supportive care.Mise à jour du récit • Jan 26
FENC: Cisplatin Ototoxicity Leadership And New Studies Will Support Strong Future Upside
Narrative Update Analysts are reaffirming a US$18 price target on Fennec Pharmaceuticals, pointing to Pedmark's role as the only approved agent for reducing cisplatin induced ototoxicity and noting that they view U.S. peak sales potential above US$300m as realistic. Analyst Commentary Bullish analysts are highlighting Fennec Pharmaceuticals as a focused oncology supportive care story, built around Pedmark as an intravenous formulation of sodium thiosulfate for reducing the risk of cisplatin induced ototoxicity.Mise à jour du récit • Jan 12
FENC: Unique Oncology Supportive Care Opportunity Will Drive Stronger Future Upside Potential
Narrative Update Overview Our fair value estimate for Fennec Pharmaceuticals edges up from $17 to $18 per share, reflecting analysts' view that Pedmark offers a unique oncology supportive care opportunity with U.S. peak sales potential cited north of $300 million and supports using a slightly higher revenue growth outlook, modestly stronger profit margins, and a lower future P/E multiple. Analyst Commentary Bullish analysts are centering their thesis on Pedmark as a differentiated oncology supportive care product, and that view is shaping how they think about valuation, execution risk, and long term growth potential.Mise à jour du récit • Dec 27
FENC: Expanded Adult Study Will Drive Stronger Future Upside Potential
Analysts have nudged their price target on Fennec Pharmaceuticals modestly higher to reflect slightly faster expected revenue growth, marginally improved profit margins, and a marginally lower projected future price to earnings multiple, supporting a fair value estimate of $17.00 per share. What's in the News Planned City of Hope investigator sponsored study will evaluate PEDMARK for preventing cisplatin induced hearing loss in adult men with stage II III metastatic testicular germ cell tumors, expanding its potential use beyond pediatrics (company announcement).Seeking Alpha • Dec 22
Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026
Summary Fennec Pharmaceuticals is a commercial-stage oncology supportive-care company centered on Pedmark/Pedmarqsi. This drug helps reduce cisplatin-induced ototoxicity in pediatric patients who are battling cancer. Pedmark is FDA-approved for pediatric patients ≥1 month, and it has shown good efficacy so far with patients. Pedmark is also the “first/only” in this drug class, and management believes they can eventually make Pedmark the standard-of-care to avoid hearing loss. Thus, despite FENC’s concentrated risk on Pedmark, I feel their outlook for 2026 is quite compelling. So, I rate the stock a “Buy” at these levels. Read the full article on Seeking AlphaMise à jour du récit • Dec 13
FENC: Expanded Hearing Loss Indication Will Drive Stronger Future Upside Potential
Analysts have raised their price target on Fennec Pharmaceuticals from 15 dollars to 17 dollars, citing updated assumptions for discount rates, growth, profitability, and valuation multiples that, despite being more conservative on margins and revenue growth, still imply a higher fair value. What's in the News City of Hope to launch an investigator sponsored study of PEDMARK in adult men with stage II III metastatic testicular germ cell tumors to prevent cisplatin induced hearing loss, expanding potential use beyond pediatrics (company announcement) Positive topline results reported from the Phase 2/3 STS J01 trial in Japan evaluating PEDMARK for reducing cisplatin induced ototoxicity in pediatric and AYA patients, with Fennec planning to pursue Japanese registration and potential partnering or licensing deals (company announcement) Completed 35 million dollar follow on equity offering of 4,666,667 common shares at 7.50 dollars per share, bolstering the balance sheet for commercialization and development initiatives (financing filing) Announced a non brokered private placement of 670,000 common shares at 7.50 dollars per share for expected gross proceeds of 5.0 million dollars, with closing targeted for November 17, 2025 (financing announcement) Lock up agreements put in place on over 28 million common shares and various equity linked awards through February 12, 2026, limiting insider and holder sales for 91 days after the November 13, 2025 offering (offering documentation) Valuation Changes Fair value estimate increased from 15 dollars to 17 dollars per share, implying a modest upward revision to intrinsic value despite more conservative operating assumptions.Article d’analyse • Apr 24
Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price Is Matching Sentiment Around Its Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) may be sending very bullish...Article d’analyse • Mar 13
US$12.60: That's What Analysts Think Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Is Worth After Its Latest Results
Shareholders might have noticed that Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) filed its full-year result this time...Article d’analyse • Nov 24
Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified
Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) shareholders are no doubt pleased to see that the share price has bounced...Article d’analyse • Oct 04
Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 2.5x Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) is...
Nouveau récit • Sep 28
Jeff Hackman's Leadership And PEDMARK's Launch Promise Robust Revenue Surge
Introduction of PEDMARK and strategic partnerships aim to boost net revenues through expanded patient access and improved distribution.Article d’analyse • Aug 15
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be
Today is shaping up negative for Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) shareholders, with the analysts delivering...Article d’analyse • Jul 16
Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • Jun 02
Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop
The Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) share price has fared very poorly over the last month, falling by a...Article d’analyse • Apr 18
Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
With a median price-to-sales (or "P/S") ratio of close to 12.9x in the Biotechs industry in the United States, you...Rendement pour les actionnaires
| FENC | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 7.9% | -1.6% | -0.8% |
| 1Y | 25.1% | 34.4% | 27.1% |
Rendement vs Industrie: FENC a sous-performé le secteur US Biotechs qui a rapporté 34.4 % au cours de l'année écoulée.
Rendement vs marché: FENC a sous-performé le marché US qui a rapporté 27.1 % au cours de l'année écoulée.
Volatilité des prix
| FENC volatility | |
|---|---|
| FENC Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: Le cours de l'action de FENC a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de FENC est passée de 9% à 14% au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1996 | 35 | Jeff Hackman | www.fennecpharma.com |
Fennec Pharmaceuticals Inc. est une société biopharmaceutique à vocation commerciale aux États-Unis. Le produit candidat de la société comprend PEDMARK, une formulation de thiosulfate de sodium pour la prévention de l'ototoxicité induite par le cisplatine chez les patients pédiatriques. Elle vend ses produits par l'intermédiaire de spécialistes régionaux en oncologie pédiatrique et de liaisons scientifiques médicales.
Fennec Pharmaceuticals Inc. Résumé des fondamentaux
| FENC statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$338.69m |
| Bénéfices(TTM) | -US$8.37m |
| Recettes(TTM) | US$51.00m |
6.8x
Ratio P/S-41.4x
Ratio P/ELe site FENC est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| FENC compte de résultat (TTM) | |
|---|---|
| Recettes | US$51.00m |
| Coût des recettes | US$3.96m |
| Marge brute | US$47.04m |
| Autres dépenses | US$55.41m |
| Les revenus | -US$8.37m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.24 |
| Marge brute | 92.23% |
| Marge bénéficiaire nette | -16.42% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de FENC?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 07:46 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Fennec Pharmaceuticals Inc. est couverte par 10 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Naureen Quibria | Capital One Securities, Inc. |